[Durable remission following donor lymphocyte infusion for post-transplant relapse of acute myeloid leukemia developing from secondary myelofibrosis]

Rinsho Ketsueki. 2022;63(12):1639-1642. doi: 10.11406/rinketsu.63.1639.
[Article in Japanese]

Abstract

Essential thrombocythemia gradually developed into secondary myelofibrosis and progressed to leukemia eight months later in a 53-year-old man. After remission induction therapy, he achieved remission by undergoing allogeneic hematopoietic stem cell transplantation from unrelated patients in non-remission. However, peripheral blood WT-1 mRNA gradually increased, and the disease relapsed three years and six months after transplantation. He was taking prednisolone (7.5 mg) and tacrolimus (5 mg) for chronic pulmonary graft-versus-host disease (GVHD) and was reluctant to reduce or discontinue immunosuppressive drugs; therefore, donor lymphocyte infusion (DLI) was performed for a total of five times. Four months after the fifth DLI, cutaneous GVHD appeared, a slow decrease in WT-1 mRNA was observed, and blasts in the peripheral blood disappeared. One year and three months after the last DLI, he achieved complete remission. Although DLI for post-transplant relapse in patients with secondary myelofibrosis or leukemia is rare, it can be beneficial for post-relapse therapy.

Keywords: Donor lymphocyte infusion; Hematopoietic cell transplantation; Myelofibrosis.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Chronic Disease
  • Graft vs Host Disease* / genetics
  • Graft vs Host Disease* / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia, Myeloid, Acute* / etiology
  • Leukemia, Myeloid, Acute* / therapy
  • Lymphocyte Transfusion
  • Lymphocytes
  • Male
  • Middle Aged
  • Primary Myelofibrosis* / etiology
  • Primary Myelofibrosis* / therapy
  • Recurrence
  • Transplantation, Homologous